Author:
Ishaq Ghauri Muhammad,Shariq Mukarram Muhammad
Abstract
Vasculitis is the inflammation of blood vessels in the human body. It causes changes and remodeling in the walls of the vessels that include thickening, narrowing and scarring. As a result, the blood flow to the organs and tissues gets restricted leading to organ damage. The cause of primary vasculitis is not known; however, most cases are thought to be autoimmune. In the present era, it is getting difficult to treat vasculitis with conventional therapies, which includes cyclophosphamide, methotrexate, azathioprine and mycophenolate mofetil, with increasing rates of relapses. Since ever, corticosteroids and cytotoxic agents or immunosuppressants have been the mainstay for treating systemic vasculitis. However, the introduction of newer biological agents have bring about a revolution in the treatment of relapses and in cases where there is failure to induce and sustain remission.
Reference32 articles.
1. Guillevin L, Dorner T. Vasculitis: Mechanisms involved and clinical manifestations. Arthritis Research & Therapy. 2007;9(Suppl 2)
2. Nakazawa D, Masuda S, Tomaru U, Ishizu A. Pathogenesis and therapeutic interventions for ANCA-associated vasculitis. Nature Reviews Rheumatology. 2019;15:91-101
3. Mahr AD, Watts RA. Eular Textbook on Rheumatic Diseases. 1st ed. London: BMJ Group; 2012. p. 616
4. Firestein GS et al. In: Erickson AR, Cannella AC, Mikuls TR, editors. Kelley & Firestein’s Textbook of Rheumatology. 10th ed. Philadelphia, PA: Elsevier; 2017. p. 1181
5. Firestein GS et al. In: Stone JH, editor. Kelley & Firestein’s Textbook of Rheumatology. 10th ed. Philadelphia, PA: Elsevier; 2017. p. 1513